NCT01053520 - Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2010

Conditions

Healthy Female Subjects

Interventions

DRUG

ABT-263

Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2

DRUG

ABT-263

Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A

DRUG

ABT-263

Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1

Trial Locations (1)

60085

Site Reference ID/Investigator# 23602, Waukegan